CMPX COMPASS THERAPEUTICS INC

Compass Therapeutics to Participate in Upcoming November Investor Events

Compass Therapeutics to Participate in Upcoming November Investor Events

BOSTON, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (“Compass”) (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that the Company will participate in the following investor events during the month of November.

Details are as follows:

Guggenheim 2nd Annual Healthcare Innovation Conference

Location: Boston, MA

Date: Monday, November 10, 2025

Time: 3:30 PM ET

Webcast Link:

Stifel 2025 Healthcare Conference

Location: New York, NY

Date: Wednesday, November 12, 2025

Time: 4:00 PM ET

Webcast Link:

Jefferies Global Healthcare Conference

Location: London, UK

Date: Thursday, November 20, 2025

Time: 12:00 PM GMT

Webcast Link:

Virtual/Replay availability: Presentations will be archived for 90 days on Compass’  page.

About Compass Therapeutics

Compass Therapeutics, Inc. is a clinical-stage oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company’s scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. Compass has built a robust pipeline of novel product candidates designed to target multiple critical biological pathways required for an effective anti-tumor response. These include modulation of the microvasculature via angiogenesis-targeted agents, induction of a potent immune response via activators on effector cells in the tumor microenvironment, and alleviation of immunosuppressive mechanisms used by tumors to evade immune surveillance. The company plans to advance its product candidates through clinical development as both standalone therapies and in combination with proprietary pipeline antibodies based on supportive clinical and nonclinical data. The company was founded in 2014 and is headquartered in Boston, Massachusetts.

Investor Contact

 

Media Contact

Anna Gifford, Chief of Staff

 

617-500-8099



EN
03/11/2025

Underlying

CMPXCOMPASS THERAPEUTICS INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on COMPASS THERAPEUTICS INC

 PRESS RELEASE
Free
CMPX COMPASS THERAPE...

Compass Therapeutics to Participate in the J.P. Morgan 2026 Healthcare...

Compass Therapeutics to Participate in the J.P. Morgan 2026 Healthcare Conference BOSTON, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics, today announced that the Company will present at the J.P. Morgan 2026 Healthcare Conference on January 14, 2026. Presentation DetailsDate: Wednesday, January 14, 2026 Time: 7:30 AM PT Webcast Link: Virtual/Replay availability: The presentation will be archived on Compass’  page. Investors interested in schedul...

December 17, 2025 1 EN
 PRESS RELEASE
Free
CMPX COMPASS THERAPE...

Compass Therapeutics to Participate in Upcoming December Investor Even...

Compass Therapeutics to Participate in Upcoming December Investor Events BOSTON, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics, today announced that the Company will participate in the following investor events during the month of December. Details are as follows: Piper Sandler 37th Annual Healthcare Conference Location: New York, NYDate: Tuesday, December 2, 2025 Time: 8:00 AM ET Webcast Link: 8th Annual Evercore Healthcare ConferenceLocation:...

November 25, 2025 1 EN
 PRESS RELEASE
Free
CMPX COMPASS THERAPE...

Compass Therapeutics Reports Third Quarter 2025 Financial Results and ...

Compass Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update Based on a continuing trend of decreased mortality in the ongoing Phase 2/3 COMPANION-002 study of tovecimig (DLL4 x VEGF-A bispecific antibody) in patients with advanced biliary tract cancer (BTC), the analyses of overall survival (OS) and progression-free survival (PFS) are expected in late Q1 2026.A new response in a third indication has been observed in the fifth and final dosing cohort of the Phase 1 dose-escalation study of CTX-8371 (PD-1 x PD-L1 bispecific antibody); no dose-limiting toxic...

November 5, 2025 1 EN
 PRESS RELEASE
Free
CMPX COMPASS THERAPE...

Compass Therapeutics Presents Preclinical Data on CTX-10726, a Differe...

Compass Therapeutics Presents Preclinical Data on CTX-10726, a Differentiated PD-1 x VEGF-A Bispecific Antibody, at the 40th Society for Immunotherapy of Cancer (SITC) Annual Meeting CTX-10726 demonstrated potent, simultaneous inhibition of tumor angiogenesis and PD-1-mediated immune suppression, and eliminated tumors in multiple preclinical studies.In vivo, CTX-10726 outperformed select competitive antibodies in the class, including ivonescimab, in controlling tumor growth across multiple xenograft and syngeneic models.IND submission is on track for Q4 2025. BOSTON, Nov. 04, 2025 (GLOBE...

November 4, 2025 1 EN
 PRESS RELEASE
Free
CMPX COMPASS THERAPE...

Compass Therapeutics to Participate in Upcoming November Investor Even...

Compass Therapeutics to Participate in Upcoming November Investor Events BOSTON, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (“Compass”) (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that the Company will participate in the following investor events during the month of November. Details are as follows: Guggenheim 2nd Annual Healthcare Innovation ConferenceLocation: Boston, MADate: Monday, November 10, 2025 Time: 3:30 PM ETWebcast Link: ...

November 3, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch